Yardstick Research tear-sheet / pharma & life sciences CRM cohort

Methodology · how we score · rubric weights in plain sight · vendors received this sheet seven days before publication and could flag factual errors, never rankings

Aktana

Identity

• Founded: UNKNOWN (company references "12 years of exclusive focus on life sciences" as of 2025, suggesting a founding around 2012-2013) [VENDOR-CLAIMED - https://www.aktana.com/]
• HQ: San Francisco, CA (inferred from life sciences tech cluster presence; not confirmed on a public about page) [UNKNOWN]
• Legal entity: Aktana, Inc. [VENDOR-CLAIMED - https://www.aktana.com/]
• Funding: Not publicly disclosed. No confirmed venture rounds found on public sources as of research date. [UNKNOWN]
• Headcount: UNKNOWN. No public headcount disclosed on vendor site or LinkedIn as of research date. [UNKNOWN]
• Acquisition: PharmaForceIQ acquired Aktana on January 7, 2026. The combined entity is described as "pharma's first end-to-end, optichannel commercial customer engagement system." [VENDOR-CLAIMED - https://www.aktana.com/blog]
• Recent news (last 12 months):
• January 7, 2026 - PharmaForceIQ acquired Aktana. The acquisition pairs Aktana's Next-Best-Action field platform with PharmaForceIQ's broader orchestration tools. [VENDOR-CLAIMED - https://www.aktana.com/blog]
• June 30, 2025 - Aktana unveiled an Agentic AI Intelligence Briefing, describing a roadmap for scaling AI integration in life sciences field operations. [VENDOR-CLAIMED - https://aktana.com/news]
• May 21, 2025 - Aktana leadership joined Grünenthal and Angelini Pharma executives at the NEXT Pharma Summit to discuss agentic AI and human-in-the-loop design. [VENDOR-CLAIMED - https://aktana.com/news]
• December 5, 2024 - Aktana announced generative AI agents designed to remain functional during CRM system transitions, directly addressing Veeva-to-Salesforce and similar migration workflows. [VENDOR-CLAIMED - https://aktana.com/news]
• November 2024 - Named a Leader and Star Performer in Everest Group's 2024 Life Sciences Next-Generation Customer Engagement Platforms PEAK Matrix. [THIRD-PARTY - https://aktana.com/news]
• Archetype: AI-driven next-best-action (NBA) and customer engagement platform built exclusively for life sciences field operations. Aktana orchestrates omnichannel HCP engagement across field reps, digital channels, and medical affairs. The Contextual Intelligence Engine generates individualized NBA suggestions delivered to field teams via mobile. The platform integrates with Veeva Vault CRM, IQVIA OCE, and Salesforce Health Cloud, making it the cohort's most deeply integrated workflow layer for commercial pharmaceutical teams.

Total score: 70 / 100

• Stage fit:
• Foundation (<40 readiness): no - Enterprise-only, no self-serve trial, requires CRM infrastructure to function. Not a fit for companies without an existing field force and CRM deployment.
• Pilot (40-59): conditional - A scoped pilot is feasible for a mid-size pharma brand with an active Veeva or Salesforce environment, but the Agentic AI features and full orchestration layer require meaningful data foundations.
• Scale (60-79): yes - Primary fit zone. 350+ brands and 1,000+ deployments across top global pharma companies is a Scale-stage signal. Named clients include Pfizer, J&J, Novo Nordisk, Genentech, Sanofi, and Abbott.
• Optimization (80+): conditional - The acquisition by PharmaForceIQ introduces integration and roadmap uncertainty typical of post-M&A periods. Optimization-stage buyers should conduct pre-commitment diligence on the combined entity's product roadmap.
• One-line verdict: The cohort's strongest AI capability for field force orchestration and the deepest CRM integration depth - limited by sparse public evidence of named customer outcomes (1/4 vendor-strength score) and post-acquisition roadmap uncertainty.

Headline numbers

Dimension scores

Pricing detail

Aktana does not publish pricing on any public surface. No tiered plan structure, rate card, or implementation fee schedule was found during research. Pricing is enterprise-negotiated.

Soft pricing-transparency penalty applied: no public pricing found. This penalty reduces the headline score by 5 points from the pre-penalty total of 75.0 to 70.0.

Given the platform's position (350+ brands, top-10 biopharma clients), pricing is consistent with enterprise commercial technology in the $200K-$1M+ annual range per client. No public data to anchor this estimate.

Integrations

Aktana documents the following technology partnerships, relevant to the pharma-lifesci-crm cohort rubric:

• Veeva Systems - Listed as a named technology partner. Aktana's field-execution platform integrates with Veeva Vault CRM for NBA delivery and HCP engagement orchestration. [VENDOR-CLAIMED - https://www.aktana.com/partners/technology-partners/]
• IQVIA - Listed as a named technology partner. Aktana integrates with IQVIA OCE (Orchestrated Customer Engagement) for omnichannel HCP engagement data. [VENDOR-CLAIMED - https://www.aktana.com/partners/technology-partners/]
• Salesforce - Listed as a named technology partner. Aktana integrates with Salesforce, including Salesforce Health Cloud, for CRM-based field orchestration. [VENDOR-CLAIMED - https://www.aktana.com/partners/technology-partners/]

Additional technology ecosystem partners include Snowflake (data warehouse), AWS, Qualtrics, Adobe, and Tableau. Specific integration depth (bidirectional field sync scope, object-level mapping) for each CRM is not publicly documented.

Editorial assessment

Aktana is the cohort's strongest purpose-built AI layer for pharma field force operations. The Contextual Intelligence Engine, 30 million+ NBA suggestions delivered, and 10 filed patents reflect genuine AI depth in a vertical where most competitors are applying horizontal ML tools to a pharma-specific problem. The 75+ use case library and 1,000+ deployments give the platform a repeatability argument that most newer entrants cannot match. The Everest Group 2024 Leader and Star Performer designation for life sciences customer engagement platforms is the strongest third-party analyst validation in the cohort for this use case.

The critical weakness the rubric surfaces is evidence. Aktana names blue-chip clients (Pfizer, J&J, Novo Nordisk, Sanofi, Genentech) but does not publish named case studies with verified methodology, peer-reviewed outcome data, or independently corroborated ROI figures. The +14% sales lift claim is presented without a named client, a time-period, or a control arm. The 30 million NBA suggestions figure is a volume metric, not a quality or outcome metric. For a vendor serving top-10 biopharma companies that have sophisticated procurement and outcomes-tracking capabilities, the absence of verifiable public evidence is the most significant trust gap in the dossier. A buyer conducting a competitive evaluation cannot independently verify Aktana's impact claims.

The January 2026 acquisition by PharmaForceIQ introduces structural uncertainty that buyers should factor in. Post-acquisition product integration, roadmap prioritization, and support-model continuity are standard risks in M&A that typically take 12-24 months to stabilize. The combined entity's description as "pharma's first end-to-end, optichannel commercial customer engagement system" signals ambition, but buyers committing to multi-year contracts should obtain written roadmap and SLA commitments from the merged entity before signing. The December 2024 CRM-transition AI agent feature - designed to maintain NBA continuity during CRM migrations - suggests Aktana anticipated some of this integration complexity.

Compliance posture is a secondary gap. HIPAA, 21 CFR Part 11, and SOC 2 certifications are not surfaced on any public page, which is a notable gap given the customer base. Buyers at FDA-regulated pharma companies will need to obtain compliance documentation through procurement channels rather than a public trust center.

Best for

• Stage: Scale (60-79). Conditional for Optimization pending post-acquisition roadmap stabilization.
• Company profile: Mid-to-large pharmaceutical, biotech, or MedTech company with an active field force of 50+ reps, an existing CRM deployment (Veeva Vault CRM, IQVIA OCE, or Salesforce Health Cloud), and a commercial technology team capable of evaluating AI-driven NBA recommendations.
• Industry fit: Core pharma commercial and medical affairs. Strong for HCP engagement orchestration, omnichannel campaign execution, and field sales intelligence at companies with branded and launch-stage products.
• Sales motion: Enterprise procurement with commercial technology and field operations stakeholders. Multi-quarter sales cycle. Post-acquisition by PharmaForceIQ, account management may shift.
• Annual tooling budget: $200K-$1M+ estimated (no public data; inference from enterprise peer positioning).
• Skip if: You need (a) independently verified named-customer outcome studies before procurement approval, (b) published HIPAA BAA, 21 CFR Part 11 documentation, or SOC 2 audit date, (c) full post-acquisition roadmap clarity before multi-year commitment, (d) transparent published pricing for budget-setting, or (e) a field force below 50 reps where the per-seat economics of an enterprise AI orchestration layer are unlikely to justify the cost.

Right-of-reply

Aktana received this tear-sheet seven calendar days before publication of the Yardstick Research 2026 Yardstick Report, including all measured numbers, sample outputs, and editorial assessment. Aktana was given the opportunity to flag factual errors - incorrect pricing, misquoted feature availability, outdated screenshots, factual misstatement in the editorial assessment. Aktana was not given the opportunity to request a score revision, dispute the rubric or its weights, withdraw from inclusion, negotiate ranking placement, or suggest changes to the editorial assessment beyond factual correction. Where a vendor flagged a factual correction, the correction was applied if verified and noted here; where a vendor disputed scoring, the dispute is recorded in the appendix but the score stands. Silence from the vendor during the right-of-reply window was treated as no objection.

Right-of-reply gaps

Specific [UNKNOWN] items surfaced in the dossier and explicitly raised with the vendor in right-of-reply:

1. HIPAA compliance status. Does Aktana sign a BAA? Published trust center or compliance page with SOC 2 audit date requested.
2. 21 CFR Part 11 support. Does the platform support 21 CFR Part 11 electronic records for FDA submission contexts?
3. SOC 2 Type II status. Held or not held? Audit date and scope?
4. ISO 27001 status. Held or not held?
5. Named customer case studies. Can Aktana provide independently verifiable named customer outcome data beyond the anonymized +14% sales lift claim?
6. Post-acquisition roadmap. What is the PharmaForceIQ integration roadmap and timeline? Which Aktana product surfaces continue unchanged post-acquisition?
7. Founding year. Year of incorporation.
8. Veeva / IQVIA / Salesforce integration depth. What is the specific data-flow architecture and bidirectional sync scope for each CRM integration?
9. Headcount post-acquisition. Combined entity headcount.

Sources

Aktana first-party: - https://www.aktana.com/ - https://www.aktana.com/platform - https://www.aktana.com/partners/technology-partners/ - https://aktana.com/news - https://aktana.com/blog

Third-party: - https://www.aktana.com/news (Everest Group PEAK Matrix citation, November 2024) - https://aktana.com/news (PharmaForceIQ acquisition announcement, January 2026) - https://aktana.com/news (Agentic AI Intelligence Briefing, June 2025) - https://aktana.com/news (NEXT Pharma Summit panel, May 2025) - https://aktana.com/news (CRM-transition AI agent announcement, December 2024)